Taking steps to plan ahead, including having difficult discussions early on, can help people with Huntington’s disease and their families navigate life as the disease progresses and care needs evolve. That’s according to speakers at the Huntington’s Disease Society of America (HDSA) annual convention, held June 26-28 in…
Treatment with a nonhallucinogenic psychedelic compound may help to ease depression in people with Huntington’s disease, according to experiments done in a mouse model. The research was done by Kaleigh Hanley, a scientist at the University of Central Florida’s College of Medicine. Hanley is one of the recipients of…
People affected by Huntington’s disease often experience stigma, but — according to two social workers, and patients themselves — this can be combated by building loving communities and being proactive about sharing experiences and asking for support. At the 40th annual convention of the Huntington’s Disease Society of…
The Huntington’s Disease Society of America (HDSA) is pushing to get 10 bills that could help provide support for people with Huntington’s disease passed in the U.S. Congress. The nonprofit is also advocating against changes to Medicaid that are currently being considered as part of the 2025 budget…
Today kicks off the 40th annual convention of the Huntington’s Disease Society of America (HDSA), an event the association says provides an opportunity for the Huntington’s disease community to come together to “learn, share, and build hope for the future.” This year’s convention is taking place in…
The first Huntington’s disease patient has been dosed in a Phase 2/3 clinical trial testing SKY-0515, Skyhawk Therapeutics‘ oral disease-modifying therapy, in adults with the neurodegenerative condition. The study, dubbed FALCON-HD (NCT06873334), is expected to enroll up to…
The Huntington’s Disease Digital Motor Score (HDDMS), a new measure based on four motor tests that are done through a smartphone app, may be able to detect Huntington’s disease progression with greater sensitivity than current standard tools, a study reports. “Our findings suggest that incorporating the HDDMS in clinical trials…
Introducing small interruptions into the abnormally long CAG repeat expansion that causes Huntington’s disease can stabilize or even reduce the length of that DNA stretch, which would be expected to slow disease progression. These are the findings of a study that tested base editing, a technique that changes a…
uniQure plans to submit a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) early next year seeking approval of its gene therapy candidate AMT-130 for Huntington’s disease. Top-line, three-year data from the ongoing clinical trials that will support that application are due in the…
Researchers have developed a modified and harmless adeno-associated virus (AAV), called AAV-DB-3, that can efficiently deliver low doses of gene therapies to deep regions of the brain impacted by neurodegenerative diseases such as Huntington’s disease. AAV-DB-3 was more than 200 times more potent at delivering its genetic cargo to…
Get regular updates to your inbox.
